Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Biogen And Isis Join For Antisense Drug
by Rick Mullin
July 9, 2012
| A version of this story appeared in
Volume 90, Issue 28
Biogen Idec and Isis Pharmaceuticals are joining to develop an Isis antisense drug for the treatment of myotonic dystrophy type 1, the most common form of muscular dystrophy in adults. Isis’ goal is to correct the underlying defect in the dystrophia myotonica-protein kinase (DMPK) gene that causes the disease. Isis will receive $12 million and is eligible for $59 million in milestone payments. Biogen Idec has the option to license the drug from Isis at any time before the completion of Phase II clinical trials.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X